Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
Haya Ascher-Svanum,1 Diego Novick,2,3 Josep Maria Haro,4 Jordan Bertsch,4 David McDonnell,1 Holland Detke11Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Windlesham, Surrey, UK; 3Departament de Psiquiatria, Universitat Autonoma de Barcelona, Spain; 4Parc Sanitari Sant Joan de...
Guardado en:
Autores principales: | Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/12667f4e45cf4e3fa8a25fb83321066f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Rosaria Di Lorenzo, et al.
Publicado: (2010) -
Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: JP Lindenmayer
Publicado: (2010) -
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012) -
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: An, et al.
Publicado: (2015) -
Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand E, et al.
Publicado: (2016)